Ignite Creation Date:
2024-05-05 @ 4:43 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00309127
Status:
COMPLETED
Last Update Posted:
2015-08-24
First Post:
2006-03-30
Brief Title:
Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy
Sponsor:
Chinese University of Hong Kong
Organization:
Chinese University of Hong Kong
Study Overview
Official Title:
A Multicentre Randomised Study to Examine the Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Disease management using a multidisciplinary team to achieve and maintain optimal metabolic and cardiovascular risk factors control in Type 2 diabetic patients with nephropathy reduces the incidence of end stage renal disease ESRD and improves clinical outcomes compared to usual clinic-based care
Detailed Description:
Diabetic patients consume over 10 of health care costs in most developed countries Over 80 of these resources are used to treat diabetic complications and late stage diseases Over 30 of patients admitted to the medical wards in Hong Kongs public hospitals have diabetes mainly due to cardiovascular and renal complications Diabetes is now the leading cause of end stage renal disease ESRD accounting for 30-50 of patients on renal replacement therapy RRT In Hong Kong the number of patients receiving RRT have increased by 50 in the last 5 years but the number of patients with ESRD due to diabetes have doubled Between 10 and 15 of patients attending medical clinics in local public hospitals either receive insulin or anti-diabetic drugs In both community and hospital settings between 30 and 50 of diabetic patients have albuminuria which is by far the most powerful predictor for early mortality cardiovascular morbidity and renal disease Local published data show that 3-10 of diabetic patients died or developed clinical endpoints yearly
There are now overwhelming evidence supporting the beneficial effects of optimal control of cardiovascular risk factors on clinical outcomes in diabetic patients However there are few studies to examine the most effective way to translate these scientific evidence collected in closely monitored clinical trial situations into daily clinical practice Results from this multi-centre randomized study will provide important information to health care policy makers regarding the cost effectiveness of disease management using a multidisciplinary team to deliver a structured care model in light of the growing diabetes epidemic and the constraints of finite resources and the need for equity
There are now overwhelming evidence supporting the beneficial effects of optimal control of cardiovascular risk factors on clinical outcomes in diabetic patients However there are few studies to examine the most effective way to translate these scientific evidence collected in closely monitored clinical trial situations into daily clinical practice Results from this multi-centre randomized study will provide important information to health care policy makers regarding the cost effectiveness of disease management using a multidisciplinary team to deliver a structured care model in light of the growing diabetes epidemic and the constraints of finite resources and the need for equity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HCPF No 121012 | None | None | None |